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ABSTRACT 
CD30 e CD30 ligando (CD30L) fanno parte, rispettivamente, della superfamiglia dei 
recettori del TNF e del TNF. Il numero di cellule T CD30+ T risulta elevato in molte 
patologie e l’interazione tra cellule T CD30+ e CD30L+ può portare sia alla 
proliferazione cellulare che all’apoptosi. Nei pazienti affetti da artrite reumatoide 
(AR), i livelli della molecola solubile del CD30 (sCD30) sembrano correlare il 
reclutamento di linfociti T CD30+ nelle articolazioni infiammate ed elevati livelli 
circolanti sono associati ad una buona risposta a terapie immunosoppressive di tipo 
sia classico che biotecnologico. Abbiamo valutato i livelli di sCD30 nel siero dei 
pazienti con AR e della molecola solubile del CD30L (sCD30L) sia nel siero che nel 
liquido sinoviale degli stessi pazienti. Inoltre, abbiamo valutato se il sCD30L fosse in 
grado di legarsi al CD30 di membrana e se fosse funzionalmente attivo. Abbiamo 
trovato alte concentrazioni di sCD30L nel siero e nel liquido sinoviale dei pazienti 
affetti da AR e siamo stati in grado di correlare alti dosaggi di sCD30 e sCD30L, 
rispettivamente, con pazienti che rispondevano o meno alla terapia con anti-TNF-α.  
Abbiamo verificato che il CD30L viene clivato e rilasciato solo quando cellule T 
CD30+ e cellule T CD30L+ vengono messe in contatto diretto. Inoltre il sCD30L lega 
il CD30 di membrana espresso costitutivamente dalle cellule Jurkat inibendone la 
proliferazione attraverso un meccanismo di tipo apoptotico. Le nostre osservazioni 
suggeriscono che il sCD30L è funzionalmente attivo e che può favorire la persistenza 
di un’infiammazione attiva inducendo l’apoptosi di cellule T CD30+, note per la loro 
azione antinfiammatoria in quanto sono preferenzialmente cellule a fenotipo Th2. 
Abbiamo studiato, inoltre, la stimolazione di cellule T CD30L+ ottenute da sangue 
periferico di donatori sani e da liquido sinoviale di pazienti con AR. I dati preliminari 
di real time PCR, dosaggio citochinico dei surnatanti e saggio di secrezione 
citochinica suggeriscono un coinvolgimento del sistema di segnale CD30/CD30L 
nella polarizzazione delle cellule T in fenotipo Th17 con caratteristiche 
proinfiammatorie. 
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Inoltre è interessante notare che nel liquido sinoviale dei pazienti con AR vi è un 
numero elevato di cellule CD30+ e che circa il 50% delle cellule T regolatorie 
esprime la molecola CD30, suggerendo un tentativo di “downmodulare” il processo 
infiammatorio. 
Infine abbiamo studiato il rilascio di citochine da parte di neutrofili stimolati con la 
CD30/Fc chimera: abbiamo rilevato un incremento nella secrezione di IL-8 con il 
doppio stimolo (CD30/Fc chimera e LPS) e un decremento nel rilascio di MMP-9 
nelle stesse condizioni di stimolo.  
In conclusione i dati ottenuti suggeriscono che il complesso sistema di signalling 
delle cellule CD30+ e CD30L+ e delle molecule solubili, è implicato nella patogenesi 
della sinovite reumatoide poichè a seconda del prevalere dell’uno o dell’altro avremo 
un effetto pro o antinfiammatorio. 
 
 
CD30 and CD30 ligand (CD30L) are members of TNF-receptor and TNF 
superfamilies respectively. CD30+ T cells are increased in several diseases and 
interaction between CD30+ and CD30L+ T cells leads either to cell proliferation or to 
cell apoptosis. In patients with rheumatoid arthritis (RA), soluble CD30 (sCD30) 
levels seem to reflect the recruitment of CD30+ T cells into the inflamed joints and 
are predictive of a positive response to classical and biological immunosuppressive 
therapy. We have evaluated levels of sCD30 in the sera of RA patients and the 
presence of soluble CD30L (sCD30L) in the sera and synovial fluid of patients with 
RA. We found high levels of sCD30L in sera and synovial fluid of RA patients; 
moreover we correlated high levels of sCD30 and sCD30L with a good or negative 
response to anti-TNF-α therapy, respectively.  
We have observed that CD30L is shedded upon direct contact of CD30+/CD30L+ T 
cells. We then wanted to define whether sCD30L binds surface CD30 molecule and 
is functionally active. Indeed sCD30L binds surface CD30 constitutively expressed 
by Jurkat cell line and inhibit cell proliferation by inducing cell apoptosis. Our 
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findings suggest that circulant sCD30L is functionally active and that it may favor 
persistence of active inflammation by inducing apoptosis of CD30+ T cells, known to 
downmodulate inflammation since they mainly belongs to the Th2 phenotype.  
We have also studied the stimulation of CD30L+ T cells obtained from peripheral 
blood of healthy donors and from RA patients’ sera synovial fluid. Preliminary data 
from real time PCR, evaluation of cytokines in the supernatant by ELISA and 
cytokine secretion assay by FACS analysis have suggested involvement of 
CD30/CD30L signalling in polarization of T cells towards a Th17 phenotype that 
have proinflammatory features. Moreover we want to mention that in the synovial 
fluid of patients with RA the number of CD30+ T cells is high and that nearly 50% of 
Treg cells express CD30, suggesting an attempt to downmodulate the ongoing 
inflammatory process.  
Finally we have investigated cytokines release by neutrophils upon CD30/Fc chimera 
stimulation: we have detected an increase in IL-8 secretion when neutrophils were 
incubated with both LPS and CD30/Fc chimera while a decrease in MMP-9 in the 
same stimulus conditions. 
In conclusion, the results obtained suggest that the complex signalling of CD30+ and 
CD30L+ cells system, also through the intervention of the soluble molecules, is 
implicated in the pathogenesis and progression of rheumatoid synovitis depending on 
the pro- or antinflammatory effect that eventually prevails. 
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INTRODUCTION 
Rheumatoid Arthritis 
Introduction 
Rheumatoid arthritis (RA) was described in the 1850s [1] but its classification criteria 
were developed only a century later [2,3]. Clinical studies considering these criteria 
identified a serious long-term disease characterized by dominant extra-articular 
features, limited treatment options, and poor outcomes [4,5]. A therapeutic revolution 
was represented by the use of anti-tumour necrosis factor (TNF) molecules and other 
biotechnological agents, leading to a better control of the disease. However, before 
this revolution, improved disease outcomes were reached through early use of 
conventional disease modifying drugs, ambitious treatment goals and better 
management of comorbidities. 
 
Pathophysiology 
RA may be considered a clinical syndrome including several disease subsets [6]. 
These different subsets involve several inflammatory cascades [7], which all lead to 
common features characterized by chronic synovial inflammation associated with 
articular cartilage and underlying bone damage. 
 
Inflammation 
One of the most important inflammatory cascade involves TNF overproduction and 
overexpression [8]. This pathway leads to synovial inflammation and consequently to 
joint destruction. This TNF overproduction could be explained by several causes, 
including interactions between T and B lymphocytes, synovial-like macrophages and 
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fibroblasts. This pathway leads to overproduction of many cytokines such as 
interleukin (IL) 6, which is able to cause persistent inflammation and eventually joint 
destruction [9]. Subforms of RA, such as juvenile idiopathic arthritis or adult-onset 
Still’s disease, differs from classical RA because are marked by the overproduction of 
other proinflammatory cytokines (eg, IL-1). Such diseases are now considered 
autoinflammatory diseases and are best treated with interleukin 1R blockade. 
 
Synovial cells and cartilage cells 
Synovial and cartilage cells represent the joints cell populations most affected by RA. 
Synovial cells can be divided into fibroblast-like and macrophage-like synoviocytes 
and these cells are involved in proinflammatory cytokines overproduction. On the 
other hand also fibroblast-like synoviocytes show an abnormal behaviour in RA. In 
experimental models, co-implantation of fibroblast-like synoviocytes with cartilage 
drives to cartilage invasion by fibroblasts [10], and this correlates with joint 
destruction [11]. Many observations have suggested that osteoclast activation plays a 
key role in bone erosion, a process that leads to joint destruction. This association 
was confirmed through an experiment in which the specific inhibition of osteoclast 
activation could reduce joint destruction without affecting joint inflammation [12]. It 
is still unclear whether arthritis starts as a primary problem in the bone and 
subsequently spreads to the joint, or on the contrary if it begins to the joint and then 
moves to the bone [13]. In favour of a start in the joint may be the observation that 
fibroblast-like synoviocytes showing altered behaviour can migrate between joints, 
suggesting how polyarthritis might develop [14]. The regulation of the inflammation 
is strictly dependent on balances between the number and type of the different 
immune cells involved. Arthritis causing immune-mediated response has been 
studied in mice in which the specific antigen is known. These experiments, 
performed in a rodent model, showed that the infusion of low numbers of T cells with 
specific characteristics led to an improvement of the arthritis, showing that T cells 
can be protective [15,16]. 
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Autoantibodies 
Rheumatoid factor (RF) was the typical autoantibody in RA. RF can be IgM or IgA 
and is a key marker directed against the Fc fragment of IgG. Other increasingly 
important antibodies are those directed against citrullinated peptides (ACPA). Most, 
but not all, ACPA-positive patients are also positive for RF suggesting that ACPA is 
a more specific and sensitive marker for the diagnosis. They also seem to be 
predictive of poor prognostic features such as progressive joint destruction [17]. 
Ongoing research has the goal to identify specific antibodies or biomarkers for 
different RA patients’ subsets and stages of the disease. 50–80% of RA patients are 
RF and/or ACPA positive. Since the antibody response varies over time, early RA is 
characterized by limited specificities while the recognition of more epitopes and the 
presence of more isotypes is specific of late stages of the disease [18,19]. Evidences 
from animal models and in vivo data suggest that ACPA have a role in the RA 
pathogenesis [20,21]. Findings of clinical studies show that RA patients positive for 
both RF and ACPA (serum positive disease) differ from those affected by the so-
called autoantibody-negative (serum negative) disease. For example, from a 
histological point of view, patient with ACPA-positive disease display a larger 
number of lymphocytes in synovial tissue, whereas those with ACPA-negative RA 
are characterized by an increased thickness of the synovial lining layer and more 
fibrosis [7]. ACPA-positive disease is associated with increased joint damage and 
low remission rates [22]. 
 
Genetics 
Genetic factors double the risk of developing RA [23]. Genome wide screening has 
allowed the identification of different genes that are associated to the risk to develop 
RA; indeed more than 30 genetic regions have been associated with RA [24-27]. At 
present, from these genetic associations, only PTPN22 and HLA genes are considered 
to have a pathogenic feature. Many risk alleles, identified in recent years, are fairly 
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common in the population and individually they display only modest effects on the 
risk of developing RA. However, ongoing researches suggest that many risk loci are 
associated to other autoimmune diseases, and some genes are involved in biological 
pathways driving the inflammation. An important aspect is the association of 
particular HLA genes with the presence of autoantibodies: indeed differences in the 
ACPA status of RA patients are related to specific HLA-DRB1 alleles [28]. These 
HLA alleles share a common motive, which is known as the shared epitope. Some 
antigens are modified by a so-called citrullination process, a post-translational 
modification in which the aminoacid arginine is converted into citrulline. This change 
is thought to allow antigens to fit in the HLA alleles that contain this shared epitope. 
The final result is the breaking of tolerance that leads to antibody formation against 
these modified self-antigens [29]. Genetic risk factors associated with RA are thought 
to be specifically associated with either ACPA-positive or ACPA-negative disease. 
The best-studied environmental factor for RA is smoking and seems to be a risk 
factor for ACPA-positive disease, especially if there is a positivity for HLA-DRB1 
shared epitope alleles [30] (Fig 1, 2).  
 
Epidemiology 
Frequency 
RA affects 0.5–1.0% of the adult population with a frequency three times higher in 
women than in men. Incidence grows up with age and is highest in women older than 
65 years, conferring a likely pathogenic role to hormonal factors [31]. The valuated 
frequencies of RA are dependent on the methods used to determine its presence 
[32,33]. In developed countries incidence ranges from 5 to 50 per 100,000 adults, is 
increasing with age [34,35] and is dependent on geographical region [36,37]. 
Northern Europe and North America are characterized by a higher prevalence of RA 
when compared with parts of the developing world, such as rural west Africa [38]. 
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These observations suggest that different genetic risks and environmental exposures 
play a role in the onset of the disease. 
Environmental risk factors 
Among environmental risk factors, smoking is certainly the most important and 
doubles the risk of developing RA [39]. However its effect seems to be restricted 
only to patients will develop an ACPA-positive disease because of its influence in the 
process of citrullination [30,40] (Fig 2). Alcohol intake, coffee intake, vitamin D 
status, oral contraceptive use, and low socioeconomic status are other potential 
environmental risk factors but evidences supporting this idea are too weak [41]. 
 
Cells in autoimmunity 
Tissue-specific autoimmune diseases, such as multiple sclerosis (MS) and RA, result 
from a loss of peripheral tolerance to self antigens. These diseases are characterized 
by an inappropriate expansion of the self-reactive effector cell population leading to 
an inflammation that is specific for a particular tissue [42]. T helper (Th) cells are 
believed to have a direct role in these diseases, but also antigen presenting cells 
(APCs) are involved in the initiation and in progression phases of the autoimmune 
response. APCs play various activities in the peripheral immune compartment and, 
during an immune reaction, are responsible of the activation of antigen-specific T 
cells through three necessary signals. The first signal is represented by presentation of 
the antigen in the context of an MHC class II molecule: this makes easy the 
recognition of the cognate antigen through the TCR by T cells. The second signal is 
generated through the interaction of adhesion and costimulatory molecules present on 
the APC, such as CD80 and CD86, with CD28 on the surface of T cells. The effect of 
this signal is to activate and expand antigen-specific T cell populations. Last signal is 
the secretion of cytokines by APCs, which drives the differentiation of activated 
antigen-specific lymphocytes into one of the effector T cell subtype. APCs are 
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responsible for the development of a particular cytokine environment that is critical 
in determining the appropriate type of immune response, which can be humoral or 
cell-mediated. Indeed, during an autoimmune reaction, the shift of autoreactive T 
cells into pathogenic and destructive effector cells depends on the secretion of soluble 
cytokines by APCs. Thus, the cytokine environment created by APCs has the ability 
to polarize T cells conferring to APCs a pivotal role in the development of an 
autoimmune response.  
 
The Th1/Th2 paradigm of autoimmunity 
According to the model proposed by Mosmann et al. in 1986, CD4+ T cells are 
divided into two distinct subsets with different effector functions [43,44]. The two 
subsets defined as Th1 and Th2 display distinct and characteristic cytokine 
expression and bioactivities as well as helper function. It was demonstrated that Th1 
cells are predominantly characterized by secretion of proinflammatory cytokines, 
such as IL-2, IL-3, TNF-α and most importantly IFN-γ, and they play a key role in 
cell-mediated functions such as the activation of macrophages; Th2 cells secrete 
cytokines, such as IL-4, IL-5, and IL-13, that lead to the stimulation of humoral 
immunity by inducing B cell activation and class switching [44]. Moreover, the 
cytokines belonging to one Th subset are able to promote the expansion of the same 
subset and at the same time to repress the development of the other one. Thus each 
Th subset is responsible for the production of a distinct cytokine pathway that causes 
the development of a specific effector function. Th1 cells have the role to induce 
proinflammatory responses, such as delayed-type hypersensitivity, and to eliminate 
intracellular infections, while Th2 cells mediate allergic reactions and anti-helminth 
responses [42]. As already mentioned, the preferential differentiation of T 
lymphocytes into Th1 or Th2 subsets depends on the cytokine environment 
influenced by APCs. Microbial components activate innate immune cells, to which 
APCs belong, via pattern-recognition receptors such as TLRs. This leads to the 
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secretion of a specific set of cytokines in order to give the proper Th1 or Th2 
response against the pathogen. APCs thus function as linker between innate and 
adaptive immune systems. It has been observed that IL-12 and IL-18, both produced 
by APCs, are able to drive a Th1-mediated response. Moreover, through a synergistic 
mechanism they upregulate their reciprocal receptors on the surface of Th1 cells 
[45,46]. On the other hand, only T cell-derived cytokines, in particular IL-4, promote 
a Th2 cell differentiation subsequent to APCs interaction. The development of 
autoimmune diseases was thought to be ruled by the Th1/Th2 subset model, in which 
Th1 cells played the role of the pathogenic T cell subset when considering tissue-
specific T cell–driven autoimmune diseases, while Th2 cells were involved in 
mediating allergic responses and asthma. Conversely Th2 cells were reported to exert 
beneficial function during tissue-directed autoimmune disease pathogenesis [47]. 
Dealing with autoimmune inflammation of the central nervous system (CNS) or 
joints, this idea took place on the basis of several observations: tissue-invading Th 
cells normally express IFN-γ [48]; Th1-inducing cytokines are present in the 
inflammatory lesion and often correlate with disease severity [49]; and experimental 
autoimmune encephalomyelitis (EAE), the animal model for MS, can be induced by 
transferring encephalitogenic Th1 cells [50,51]. Indeed, mice treated with Th1-
inducing cytokines showed a worsening of the autoimmune disease, such as EAE and 
collagen-induced arthritis (CIA), the animal model for RA. However, studies with the 
aim to generate and immunize mice deficient in Th1 cytokines, such as IFN-γ and 
TNF-α, demonstrated that they were not protected from autoimmune disease. Indeed, 
if compared to wild type (WT) mice, TNF-α–deficient ones showed the same disease 
progression and severity in both EAE and CIA, while IFN-γ– and IFN-γ receptor– 
deficient mice were more susceptible to the disease [52,53]. Moreover, in disease-
resistant mouse strains, loss of IFN-γ leads to a higher susceptibility to EAE [54]. 
Generally, the progression of autoimmune disease is not affected by deletion of Th2 
cytokines [55]. These last observations show that Th1 cytokine deficiency is related 
to a worsening of the disease, thus suggesting a protective role for Th1 cytokines. 
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Despite this contradiction, autoimmunity has continued to be handled considering the 
Th1/Th2 paradigm mostly due to data describing autoimmune disease in mice 
deficient either in the transcription factor for IFN-γ or in Th1-inducing cytokines. T-
box expressed in T cells (T-bet) is the key transcription factor for Th1 cell 
development and IFN-γ production, and mice lacking T-bet do not produce neither 
Th1 cells nor IFN-γ [56,57]. According to the role, conferred in Th1/Th2 paradigm, 
for Th1 cells and IFN-γ in autoimmunity, T-bet–deficient mice are resistant to the 
induction of many autoimmune diseases, such as EAE, inflammatory bowel disease 
(IBS), and systemic lupus erythematosus (SLE) [58-61]. Protection from disease is 
correlated to an unbalanced ratio of the Th1/Th2 response in favour of a Th2 
environment that included significant upregulation of the Th2 cytokines IL-4, IL-5, 
and IL-10. The inhibition of GATA-binding protein 3 (GATA-3), on the other hand, 
down-regulates the expression of Th2 cytokine, leading to a decrease of allergic 
airway inflammation and hyperresponsiveness [62]. It has also been reported an 
imbalance in the Th1/Th2-inducing transcription factors during human disease: 
patients with relapsing-remitting MS show an up-regulation of the expression of T-
bet in peripheral blood leukocytes during relapse [63]. Conversely, patients with 
asthma are characterized by increased gene expression of GATA3 and reduced 
expression of T-bet in their airways [64,65]. Considering above data, strategies for 
the treatment of autoimmune inflammation have focused on the concept of immune 
deviation [66], favouring an environment in which there is an expansion of the Th2 
phenotype. Thus, while the Th1/Th2 paradigm of autoimmunity has shown 
conflicting data, experiments demonstrating that mice deficient in Th1-inducing 
cytokines or T-bet, are resistant to the induction of antigen-driven autoimmune 
diseases, provide support to this hypothesis.  
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Th17 cells 
The discovery of a new Th cell subset by Langrish et al. [67], moved researchers’ 
attention towards the regulation of IL-17 cytokine expression by the so-called Th17 
cells. IL-17 (also known as IL-17A) is a proinflammatory cytokine that induces the 
synthesis of IL-1, IL-6, G-CSF and chemokines, by a variety of distinct cells such as 
fibroblasts, stromal cells and endothelial cells [68-74]. The secretion of this cytokine 
is due entirely by CD4+ Th17 cells, which also produce IL-17F (another IL-17 family 
member, with the closest sequence identity to IL-17A), IL-6, TNF-α and IL-22 
[67,75-78]. Th17 subset is now considered the population that plays a pivotal role in 
the pathogenesis of autoimmunity. Human autoimmune diseases, such as RA [79,80] 
and MS [81,82], have been associated with the expression of IL-17 and its inhibition 
or deletion in the corresponding animal models has shown a varying degree of 
protection [67,83-86]. The differentiation of naïve CD4+ T cells into either polarized 
Th17 cells or autoimmunity-suppressing Tregs depends on a delicate balance of 
cytokines. TGF-β induces the polarization of CD4+ T cells into Tregs in the absence 
of IL-6 in vitro, while the addition of this cytokine shifts the balance toward the 
proinflammatory Th17 phenotype. Moreover this process is strengthen by IL-1β and 
is negatively regulated by Th1 and Th2 cytokines [86-88]. Th17 cells differentiation 
requires, in vitro and in vivo, induction of the transcription factor retinoic acid–
related orphan receptor-γt (ROR-γt), which is characteristic of this T cell subset [89]. 
Considering this emerging T cell subset, some of the previously observed conflicting 
data in the Th1/Th2 paradigm of autoimmunity could be explained, especially the 
discrepancies obtained for IL-12p40– and IL-12p35–deficient mice: lymphocytes 
obtained from EAE-resistant IL-12p40–/– mice showed defects in Th1 and Th17 
responses, while cells from susceptible IL-12p35–/– mice, which still express IL-23, 
lack Th1 development but have an elevated frequency of Th17 cells [90,91]. 
According to these findings, EAE-resistant IL-23p19–/– mice showed normal Th1 
responses but had significantly reduced IL-17 production [67]. Adoptive transfer 
experiments showed that encephalitogenic CD4+ T cells, previously treated in vitro 
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with antigen and IL-23, but not IL-12, could induce EAE in recipient mice [67]. 
Accordingly to the thesis that IL-23 is critical for the expansion and survival of Th17 
cells, it has been demonstrated that IL-23 is required during the effector phase of 
EAE [92,93]. Moreover, Cua et al. observed that injection of IL-23 into the CNS of 
p19–/– mice cancelled the resistance to develop EAE [94]. The hypothesis suggested 
was that the role of IL-23 in promoting encephalitogenicity results from its activation 
of macrophages in the inflamed CNS to produce proinflammatory cytokines such as 
IL-1 and TNF. If right, this idea would confer an important role to IL-23 in the 
regulation of myeloid cells in organ-specific autoimmune diseases. However, the 
precise involvement of IL-23 in autoimmunity, when excluded its direct effect on Th 
cells, still needs to be clarified.  
The above findings with regard to IL-12 and IL-23 in the context of CNS 
autoimmune inflammation were also reproduced in the animal model of autoimmune 
joint inflammation (i.e., CIA) [94,95]. IL-23–deficient mice are resistant to disease 
development and do not show pathological features upon histological examination of 
the joints. IL-12p35–/– mice, however, show an enhanced CIA severity and a delayed 
disease recovery when compared to WT mice, although no differences at 
histopathological level was found [94]. IL-23 or IL-12 deficiency does not affect 
arthritis development at the level of collagen type II–specific T cell proliferation; 
however, gene expression analysis demonstrated a downregulation of IFN-γ 
transcripts and an upregulation of IL-1β, IL-6, IL-17, TNF, and nitric oxide synthase 
2 ones in IL-12–deficient mice. Although levels of IFN-γ were increased, there was 
no difference in the expression of IFN-γ–associated chemokines in the joints of IL-
12–/– mice. These observations support the hypothesis that IL-23 and not IL-12 is 
required for mediating the pathogenesis of autoimmune joint inflammation, which is 
subsequently, in a certain way, modulated by the IL-12/IFN-γ pathway. 
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CD30/CD30L 
Gene Structure and Expression of CD30 
CD30 is a member of the tumour necrosis factor receptor (TNFR) superfamily that 
includes, among others, TNFR, CD40, Fas (CD95) and OX-40 (CD134) [96]. Human 
CD30 is a type 1 glycoprotein, containing both N- and O-linked sugars, with a 
molecular weight ranging from 105 to 120 kDa [97]. Protein cytoplasmic region is 
characterized by the presence of several serine/threonine phosphorylation sites, which 
regulate cell signalling upon receptor engagement. Mature form of human CD30 is a 
577 amino acid peptide, subdivided in a 365 amino acid extracellular region, a 24 
amino acid transmembrane segment and a 188 amino acid cytoplasmic domain [97]. 
The pre-processed form of the transmembrane protein includes an additional 18 
amino acid signal sequence. From a structural point of view, human CD30 is made up 
of six cysteine-rich repeats in the extracellular domain, a characteristic of this family, 
with an interposed 60 amino acid partial repeat [98]. An 85 kDa soluble form of 
CD30 (sCD30) is produced upon proteolytic cleavage and can be found in the blood 
of patients with CD30 positive lymphomas or autoimmune and allergic diseases [99]. 
An isoform of CD30, generated by alternative splicing of the transcript (isoform 2), 
was described, and is characterized by a 132 amino acid N-terminal sequence in the 
cytoplasmic region. Among species, the CD30 coding regions are relatively well 
conserved showing a sequence identity of 64% between human and mouse, of 58% 
between human and rat and of 97% between human and chimpanzee. In non-
pathological conditions, activated B and T-lymphocytes and NK cells generally show 
a good CD30 expression while lower levels of expression were observed for activated 
monocytes and eosinophils [100]. Moreover, CD30 is found on a small percentage of 
CD8+ T cells while only a negligible expression on naïve or resting lymphocytes has 
been described [101]. Among mechanisms able to trigger CD30 expression on T 
cells, mitogen activation, antigen receptor cross-linking and viral infection have been 
reported [102]. Histological analysis of normal tissues showed CD30 expression in a 
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rare population of large lymphoid cells in sections of lymph node, thymus, tonsil and 
endometrial cells with decidual changes [103]. Importantly, CD30 expression is 
mainly related to cells belonging to the immune system. The interest on CD30 
molecule was originally due to its strong cell surface expression on Reed-Sternberg 
(R-S) cells, the malignant cell-population in Hodgkin’s disease (HD) and the 
molecule is used as a diagnostic marker for this lymphoma [104]. CD30 is also 
expressed on subsets of Non-Hodgkin Lymphomas (NHL), on anaplastic large cell 
lymphoma (ALCL) tumour cells and on some rare solid tumours, including 
embryonal carcinomas and seminomas [105-108]. A correlation between elevated 
levels of sCD30 in the sera of patients affected by ALCL [109] or HD [104,110] and 
poor disease prognosis has been reported.  
As far as autoimmune diseases concerns, CD30 shows high expression levels on 
activated lymphocytes in MS and systemic sclerosis (SSc) patients. As for 
hematologic malignancies, elevated levels of sCD30 were detectable in the sera of 
these patients and the levels frequently correlated with disease severity [111,112]. 
High levels of sCD30 were also found in the sera of patients infected by one of many 
different viruses, such as hepatitis B and C, human immunodeficiency virus (HIV) 
and Epstein-Barr virus (EBV). Increased levels of sCD30 have been found in sera of 
patients with chronic inflammatory diseases such as SLE or RA [113-119] and SSc 
[111], with allergic diseases such as atopic dermatitis (AD) [120-123], asthma 
[124,125], rhinitis [126]. High serum levels of sCD30 represent an independent 
predictor of disease progression and poor prognosis for patients with CD30-positive 
lymphomas, autoimmune diseases or viral infections. 
 
Gene Structure and Expression of CD30L 
CD30L belongs to the TNF family [97] and is the only known ligand for CD30. It is a 
234 amino acid type II, single pass transmembrane protein and its calculated 
molecular weight is of 26 kDa. Human CD30L gene has been reported to be located 
	   16	  
on chromosome 9q33 [127] and shows significant structural similarities to TNF-α, 
TNF-β, CD40 ligand (CD40L) and Fas ligand (FasL) [96]. At RNA transcripts level, 
CD30L is found in B cells, activated T cells, macrophages, granulocytes, eosinophils 
and some HTLV-1-positive T cell lines [128-135], while at protein level, CD30L is 
detected on activated peripheral blood T cells, B cells, neutrophils, mast cells, 
monocytes and macrophages [136]. Among species, the CD30L gene sequence is 
well conserved showing a sequence identity of 78% between human and mouse, of 
86% between human and dog and of 99.5% between human and chimpanzee. Only 
one isoform has been described for CD30L and this sequence lacks the consensus 
proteolytic cleavage motif found in many TNF family members. Nevertheless a 
soluble form (sCD30L) has been detected but its biological role is still unclear [137]. 
 
Signalling and Biological Functions of the CD30/CD30L System 
Activation of the CD30 receptor following ligand engagement or cross-linking by 
immobilized antibodies leads to a mechanism of trimerization and recruitment of 
signalling proteins. CD30 protein does not contain an enzymatic domain, thus signal 
is transduced exclusively by members of the TNFR-associated factor (TRAF) family 
and various TRAF-binding proteins. It is observed that upon binding of CD30 to its 
ligand the intracellular levels and sub-cellular localization of TRAF2 is altered 
[138,139]. Signal mediated by CD30 engagement involves many different pathways, 
including MAP kinases and NF-κB [140,141]. These pathways are strongly 
dependent on the cell types and co-stimulatory signals involved, leading to 
mechanisms capable of promoting cell proliferation, cell survival or antiproliferative 
effects and cell death. For example, it was observed that in ALCL cells, the induction 
of CD30 signalling by an anti-CD30 antibody causes apoptotic cell death with a 
selective downregulation of TRAF2 expression and a reduced ability to activate NF-
κB [142]. On the other hand, on HD and other tumour cell lines, the same anti-CD30 
antibody stimulation was able to induce proliferation of these cells [129]. The 
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molecular mechanism at the basis of this variety of responses in different tumour cell 
types to anti-CD30 antibodies is not completely understood. However, it has been 
suggested that the constitutive NF-κB activation pathway present in some tumour cell 
lines, is the key player for different outcome in the response [142]. Supporting this 
idea, it was observed that the stimulation of CD30 on HD cells membrane together 
with the inhibition of NF-κB by bortezomib (a proteasome inhibitor) resulted in 
enhanced therapeutic effects in both, in vitro and in vivo systems [143]. 
CD30/CD30L system is related also to immune system: CD30 can act as a co-
stimulatory molecule of the CD3/TCR complex [144,145]. Moreover, in experiments 
based on CD30 deficient mice, it was demonstrated that CD30 is involved in the 
regulation of immune cell memory functions because these mice showed an impaired 
capacity to sustain follicular germinal center responses and a substantially reduced 
recall memory antibody responses [146,147]. The signal triggered by CD30 
engagement has the ability to downregulate cellular immune response on activated T 
and B cells and to induce cell death of thymocytes in the negative selection process of 
autoreactive T cells [105,144,145]. 
Reverse signalling via TNF family ligands is not completely proven but a few 
examples in the literature give evidence that suggests the possibility for a reverse 
signalling via CD30L. For example, the stimulation of CD30L on neutrophils led to 
an oxidative burst and to the production of the proinflammatory chemokine IL-8. In 
the same way, activated peripheral T cells enhanced IL-6 secretion and proliferation 
upon CD30L cross-ligation [134]. Another experiment showed that stimulation 
through CD30 on CD30L expressing mast cells result in degranulation-independent 
secretion of chemokines, including IL-8, macrophage inflammatory protein-1α (MIP-
1α) and MIP-1β [148]. Taken together, these observations indicate that CD30/CD30L 
signalling leads to different responses, which are dependent, first of all, on the 
considered cell type and secondly on their activation- and/or transformation status.  
Considering autoimmune and chronic inflammatory diseases, several studies have 
provided evidences that CD30/CD30L signalling is involved in Th2 cell responses 
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and Th2-associated diseases [149,150]. However, recent observations have shown 
that CD30/CD30L signalling plays a role also in Th1 and Th17 responses and in Th1-
associated diseases [151-154]. Furthermore, it is also involved in the regulation of 
memory T cell response: in a murine transplantation model, antigen-induced T 
regulatory (Treg) cells, but not naïve ones, were able to suppress allograft rejection 
mediated by memory CD8+ T cells in an Ag-specific manner [155]. This suppression 
was related to an enhanced apoptosis of allospecific memory CD8+ T cells in the graft 
due to the presence of CD30 expressing Treg cells and to the CD30/CD30L 
interaction [156,157]. More observations supporting these data came from an 
experiment demonstrating that CD30 signalling is important for expansion of Treg 
cells in the prevention of acute graft-versus-host disease [158]. As reported above, 
high serum levels of sCD30 are detectable during viral infections, allergic and 
autoimmune disorders.  
Focusing on RA, patients affected by the disease showed increased levels of sCD30 
in both serum and synovial fluid (SF) [159]. This feature could be due to the presence 
of CD30+ synovial T lymphocytes, recruited at the site of tissue damage with the aim 
to downmodulate inflammation [160]. It is thought that CD30+ T lymphocytes belong 
mainly to the Th2 subset, but they also show the ability to produce both IFN-γ and 
IL-4 (Th0 lymphocytes). RA is considered primarily a Th1-driven condition 
[161,162] although the presence of increased levels of Th2 cytokines, such as IL-4 
and IL-10, is found in the early stages of the disease [159]. It has been reported that 
IL-4 has the ability to induce CD30 membrane expression [163] and increased levels 
of IL4 were found in both SF and serum of RA patients [164]. CD30/CD30L 
signalling could play a potential role in the pathogenesis of RA because it has been 
shown, in animal models, that sCD30 is able to inhibit CD30/CD30L interaction and, 
at the same time, activate CD30L by reverse signalling [152]. Moreover inhibition of 
CD30/CD30L signalling by sCD30 leads to a strong decrease in Th1 cytokines 
production, such as for IFN-γ, conferring to this mechanism a potential relevant role 
in the control of a Th1-response. These data may be crucial for the understanding of 
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the cellular mechanisms underlying clinical response to classical and biological 
disease modifying drugs since it has been shown that sCD30 levels correlate with 
response to treatment [165,166]. 
CD30/CD30L signalling is also involved in Th17 induction. CD4+ T cells taken from 
CD30L- or CD30-deficient mice showed a reduced ability to differentiate into Th17 
cells but, if cultured in vitro under Th17-polarizing conditions, they were able to 
enhance IL-2 production. Moreover, it was observed that a neutralization of IL-2, 
using an anti-IL-2 mAb, partly restored the ability of Th17 differentiation in CD30L–
/– or CD30–/– T cells. Additional CD30L cross-linking with immobilized anti-CD30L 
mAb caused a suppression of IL-2 production by CD30–/– CD4+ T cells, indicating 
that the pathway triggered by CD30L stimulation is responsible for the 
downregulation of IL-2 production [161]. In vivo experiments showed that 
transfection of CD30L–/– CD4+ T cells in severe combined immunodeficiency (SCID) 
CD30L-deficient mice leads to an altered Th17 differentiation, while transferring 
CD30L+/+ CD4+ T cells causes a normal Th17 differentiation. The data suggest that 
CD30L/CD30 signalling carried out by the T–T cell interaction plays a critical role in 
Th17 cell differentiation, at least partly via downregulation of IL-2 production. [135]. 
This observation was strengthened by studies with the aim to clarify the role of 
CD30L in the development of colitis experimentally induced by dextran sulfate 
sodium (DSS), in which IL-17 is involved in the pathogenesis [144]. CD30L-
deficient mice were resistant to both acute and chronic colitis induced by 
administration of DSS. Moreover, if compared with WT mice, CD30L-deficient mice 
showed significant lower levels of IFN-γ, IL-17, and IL-10 but higher levels of IL-2 
in lamina propria T lymphocytes. Soluble murine CD30-Ig fusion protein, which was 
capable of inhibiting Th17 cell differentiation in vitro, ameliorated both types of DSS 
induced colitis in WT mice. Modulation of CD30L/CD30 signalling by sCD30 could 
be a novel biological therapy for inflammatory diseases associated with Th17 
responses. 
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AIM OF THE PROJECT 
 
This PhD project has the aim of studying the role of CD30/CD30L+ T cells and of 
CD30 and CD30L soluble molecules in the pathogenesis of rheumatoid synovitis. To 
this purpose we have evaluated the level of sCD30 and sCD30L in both serum and SF 
of RA patients and have verified whether it may be used as prognostic marker of 
response to treatment with both traditional disease modifying antirheumatic drugs 
and with biologics.  
We also wanted to verify whether sCD30L is functionally active by binding CD30+ 
cells and by inducing or blocking cell growth. Moreover we have evaluated in which 
way sCD30L is shedded and which biological conditions may favor this process. 
As a second step we wanted to analyze the percentage and phenotypic characteristics 
of CD30+ and CD30L+ T cells in RA PB and SF in order to evaluate the impact of 
CD30/CD30L signalling in the pathogenesis of RA.  
Finally, we wanted to clarify whether CD30+ cells or CD30/Fc chimera are able to 
induce a signal transduction in CD30L+ T cell by analyzing the cytokine production. 
Since neutrophils express CD30L and play a pivotal role in the pathogenesis of RA 
we have studied the effect of CD30L binding by CD30/Fc chimera in this cell 
population. 
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MATERIALS AND METHODS 
 
Patients 
We enrolled 138 patients fulfilling the classification criteria for RA of the American 
College of Rheumatology/European League against Rheumatism [167,168]. Sera 
were collected before the beginning of the treatment. 
One hundred age and sex matched healthy donors (25 males and 75 females) were 
enrolled as controls. Characteristics of patients and controls are reported in Table 1. 
Sera were tested for sCD30 and sCD30L. 
Blood samples were obtained from patients and controls after informed written 
consent. The study was approved by the Verona Hospital ethical committee. 
 
Soluble CD30 and CD30Ligand detection  
sCD30 was quantified in serum of 138 RA patients and 100 healthy donors and in SF 
of 10 patients and controls using an ELISA commercial kit (Bender MedSystems, 
Vienna, AT), according to the manufacturer’s instructions. Briefly, for sCD30 
molecule, 25 µL of serum or SF and 50 µL of HRP-conjugated antibody were 
incubated for 3 hours at room temperature in 96-well microplates coated with specific 
antibody. For the detection of sCD30L molecule, 50 µL of serum or SF and 50 µL of 
biotin-conjugated antibody were incubated for 2 hours at room temperature in 96-
well microplates coated with specific antibody. The enzymatic reaction was read at 
450 nm with TECAN Sunrise III (Tecan, Männedorf, CH). 
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Isolation of PBMCs and SFMCs 
Peripheral blood mononucleate cells (PBMCs) and synovial fluid mononucleate cells 
(SFMCs) were isolated from heparinized blood and synovial fluid treated with 
hyaluronidase (Sigma, St. Louis, MO) through density gradient centrifugation using 
Lymphoprep Ficoll-Isopaque (Axis-Shield, Oslo, NO) according to manufacturer’s 
instruction. 10 mL PB or SF were diluted with 10 mL PBS and then layered over 10 
mL Lymphoprep in a 50 mL centrifuge tube. Samples were centrifuged at 800 x g for 
20 minutes and cells collected using a Pasteur pipette. Obtained cells were washed 
twice with PBS at 1200 rpm for 10 minutes and then counted using acridin orange 
staining in a Burker chamber. 
 
PBMCs and SFMCs immunophenotype by FACS analysis 
Immunophenotype analysis was carried out on PBMCs and SFMCs obtained from 14 
RA patients and 8 controls (healthy donors with post-traumatic synovits). Cells from 
each sample were splitted into three tubes, containing 1 x 106 cells, and stained with 
different monoclonal antibodies. Tube for CD30 detection contained APC-H7 
conjugated anti-CD4 antibody (5 µL), FITC conjugated anti-CD8 antibody (10 µL), 
PerCp conjugated anti-CD3 antibody (10 µL) and PE conjugated anti-CD30 antibody 
(10 µL); tube for CD30L contained APC-H7 conjugated anti-CD4 antibody (5 µL), 
FITC conjugated anti-CD8 antibody (10 µL), PerCp conjugated anti-CD3 antibody 
(10 µL) and PE conjugated anti-CD30L antibody (20 µL); finally tube for Treg cells 
contained APC-H7 conjugated anti-CD4 antibody (5 µL), FITC conjugated anti-
CD25 antibody (20 µL), PerCp conjugated anti-CD3 antibody (10 µL), PE-Cy7 
conjugated anti-CD127 antibody (5 µL) and PE conjugated anti-CD30 antibody (10 
µL). Samples in each tube were incubated for 20 minutes at room temperature 
protected from the light. Treg tube was then fixed, permeabilized and incubated with 
ALEXA647 anti-FOXP3. Briefly, cells were washed with 2 mL wash buffer at 250 x 
g for 10 minutes. Then they were fixed with Human Foxp3 Buffer A for 10 minutes 
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at RT in the dark. Cells were washed and then permeabilized incubating 0.5 mL 
working solution Human Foxp3 Buffer C for 30 minutes at RT in the dark. Cells 
were then washed and incubated with ALEXA647 conjugated anti-FoxP3 antibody 
(20 µL) for 30 minutes at RT in the dark. All reagents were purchased by Becton 
Dickinson (San Jose, CA, USA), except for anti-CD30L monoclonal antibody (R&D 
System, Minneapolis, MN, USA). Samples were analysed on a FACSCanto 
cytometer (Becton Dickinson). The sensitivity of fluorescence detectors was set and 
monitored using Calibrite Beads (Becton Dickinson) according to the manufacturer’s 
recommendations. Data were analyzed by FlowJo 9.3.3 software (Tree Star, Ashland, 
OR). 
 
Immunoprecipitation of sCD30L from RA patients’sera 
sCD30L was immunoprecipitated from serum of RA patients. Briefly, 500 µL of 
normal or RA patients serum (200 ng/mL sCD30L) or 40 ng of recombinant human 
sCD30L (Bender MedSystems) were immunoprecipitated with 20 µL of protein-A-
Sepharose packed beads (Sigma) precoated with 10 µg of CD30/Fc chimera (R&D 
Systems, Minneapolis, MN, USA). After extensive washing with PBS, the specific 
immunoprecipitate, eluted by boiling for 5 min in 40 µL of reducing sample buffer 
(10% glycerol, 1% SDS, 0,01 bromophenol blue, 0.05 DTT, 0.045 Tris-HCl, pH 6.8), 
was resolved by 10% SDS-polyacrylamide gel electrophoresis (PAGE) and 
transferred onto a nitrocellulose membrane (Hybond-C Extra, Amersham, Little 
Chalfont, UK) using an electroblotting apparatus (Bio-Rad, Hercules, CA, USA) in 
transfer buffer pH 8.3 (25 mM Tris-base, 192 mM glycine, 20% methanol). 
Immunoblot detection of sCD30L was carried out with the ECL system (Amersham) 
using a goat anti-human CD30L primary antibody (R&D Systems) at 1 µg/mL and a 
1:10.000 horseradish peroxidase-conjugated donkey anti-goat secondary antibody 
(Santa Cruz biotechnology, Santa Cruz, CA, USA). 
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Binding of sCD30L to CD30+ T cell line by FACS analysis 
Jurkat CD30 positive cell line (human acute lymphoid leukemia - DSMZ, 
Braunschweig, DE) was grown in RPMI-1640-GlutaMAX I, supplemented with 10% 
foetal calf serum (FCS), 50 U/mL penicillin and 50 µg/mL streptomycin (all 
purchased from Life Technologies, Carlsbad, CA, USA). Cells were washed with 
PBS and resuspended at a concentration of 5 x 106 cells/mL. 100 µL of cell 
suspension were incubated 1 hour at room temperature with 6 or 32 µg of human 
recombinant sCD30L (Bender MedSystems) or with 40 µL of sera from RA patients 
or from normal controls, previously tested for the presence of sCD30L (160, 400 and 
0 ng/mL respectively) or with 40 µL of FCS (as negative control). The presence of 
sCD30L on cells was revealed by incubation with 5 µL of anti-human sCD30L-biotin 
conjugated monoclonal antibody (Bender MedSystems) (1 hour at 4°C), and 
streptavidin-phycoerytrin (SA-PE) (Becton Dickinson, San Jose, CA). Cells were 
also surface stained by standard protocol, as detailed elsewhere (30), with anti-human 
PE-tagged CD30 monoclonal antibody (DakoCytomation, Glostrup, DK). Cells were 
acquired on a FACSCalibur cytometer (Becton Dickinson). Analysis was performed 
with FlowJo 9.3.3 software (Tree Star). 
 
Co-culture of DG75 with Karpas-299 cell lines 
A CD30L positive B cell line (DG75, human Burkitt lymphoma - DSMZ) was 
cultured with a CD30 positive T cell line (Karpas-299, human T cell lymphoma - 
DSMZ). 1 x 106 cells of each cell line were seeded in a 24-wells plate (Becton 
Dickinson) at a final volume of 1 mL and cells were cultured alone or together. 
Moreover, Karpas-299 cells were also seeded in the upper chamber of a 0.4 µm pore 
size transwell culture system (Corning, New York, NY) and DG75 cells in the lower 
one. Cells were incubated for 6, 24, 48 and 72 hours in RPMI + 10% FBS at 5% CO2. 
For each condition, CD30L+ cells were stained for 20 minutes at room temperature 
	   25	  
with 20 µL PE anti-CD30L (R&D System) either before or after the culture. Cells 
were then stained with 5 µL APC anti-CD19 (Becton Dickinson) monoclonal 
antibody. Preliminary experiments were carried out to exclude capping phenomena. 
sCD30L was evaluated in cell culture supernatants using an ELISA commercial kit 
(Bender) as already described. 
 
Proliferation assay 
Jurkat cells were seeded in 96-well plates at 25 x 103 cells/well in RPMI + 40% 
human normal or RA serum with high (180 ng/mL) or undetectable sCD30L level. 
Sera were also preincubated 2 hours with 3 µg/mL anti-CD30L monoclonal 
neutralizing Ab to block sCD30L activity. Preliminary experiments were done to 
exclude a possible effect of this Ab on cell viability. After 72 hours of culture, the 
number of cells in different conditions was measured by MTT incorporation. The 
percentage of proliferation inhibition was calculated as percentage difference 
between cell number cultured with normal serum and cell number cultured with RA 
serum. 
 
Apoptosis 
Internucleosomal DNA fragmentation was quantified with an ELISA assay (Roche 
Biochemical, Mannheim, D) according to the manufacturer’s instructions. Briefly, 1 
x 104 cells were seeded in 96-wells microtiter plates and incubated for 24 hours with 
40% of normal or RA patients’ sera. After 72 hours cells were harvested and 
incubated with lysis buffer. The enrichment of mono- and oligonucleosomes released 
into the cytoplasm was calculated as ratio between absorbance of cells cultured with 
RA patients’ sera and absorbance of cells cultured with human normal sera. 
Enrichment factor was used as index of apoptosis and shown on the y-axis as mean ± 
SD. 
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CD30 and CD30L expression time course 
PBMCs from healthy donors were activated with Dynabeads Human T-Activator 
CD3/CD28 (Life Technologies). Cells and beads were putted in a 14 mL 
polypropylene round-bottom tube in a ratio of 1:1 and incubated for 6, 10, 15, 20, 24 
and 48 hours in RPMI + 10% FCS at 5% CO2. Cells were harvested, washed and 
stained for 20 minutes at RT in the dark with APC anti-CD3 (Becton Dickinson) and 
PE anti-CD30 (Becton Dickinson) or PE anti-CD30L (R&D System) antibodies. 
Cells were acquired on a FACSCalibur cytometer (Becton Dickinson). Analysis was 
performed with FlowJo 9.3.3 software (Tree Star). 
 
PBMCs and SFMCs stimulation by CD30 chimera 
PBMCs and SFMCs were activated as written above and cultured in presence or 
absence of 20 µg/mL CD30/Fc chimera (R&D Systems) for 24, 48 and 120 hours and 
15, 24 and 48 hours respectively. Cells were collected for RNA extraction and 
supernatants for cytokine levels evaluation. 
 
RNA isolation and RT PCR 
Total RNA was extracted from PBMC using TRIzol reagent (Invitrogen), following 
manufacturer’s instructions. First-strand cDNA was generated using the SuperScript 
III First-Strand Synthesis System for RT-PCR Kit (Invitrogen), with random 
hexamers, according to the manufacturer’s protocol. RT product was aliquoted in 
equal volumes and stored at -20°C. 
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Cytokines production evaluated by Real Time RT PCR 
PCR was performed in a total volume of 25 µL containing 1× Taqman Universal 
PCR Master mix, no AmpErase UNG and 2.5 µL of cDNA; pre-designed, Gene-
specific primers and probe sets for each gene (IL-17 Hs00174383_m1, IL-4 
Hs00174122_m1, IL-6 Hs00985639_m1, IFN-γ Hs 00989291_m1, IL-10 Hs 
00961622_m1) were obtained from Assay-on-Demande Gene Expression Products 
(Applied Biosystems). Real Time PCR reactions were carried out in a two-tube 
system and in singleplex. The Real Time amplifications included 10 minutes at 95°C 
(AmpliTaq Gold activation), followed by 40 cycles at 95°C for 15 seconds and at 
60°C for one minute. Thermocycling and signal detection were performed with 7500 
Sequence Detector (Applied Biosystems). Signals were detected according to the 
manufacturer’s instructions. This technique allows the identification of the cycling 
point where PCR product is detectable by means of fluorescence emission (Threshold 
cycle or Ct value). As previously reported, the Ct value correlates to the starting 
quantity of target mRNA. Relative expression levels were calculated for each sample 
after normalization against the housekeeping gene GAPDH, using the ΔΔCt method 
for comparing relative fold expression differences. The data are expressed as fold 
change. Ct values for each reaction were determined using TaqMan SDS analysis 
software. For each amount of RNA tested triplicate Ct values were averaged. Because 
Ct values vary linearly with the logarithm of the amount of RNA, this average 
represents a geometric mean. 
 
Cytokines secretion evaluated by ELISA kit 
Supernatants of the previously described experiment were tested for cytokine levels 
using commercial ELISA kit purchased from R&D Systems (Human Quantikine 
ELISA). For normal PBMCs were evaluated levels of IL-6, IL-4, IFN-γ and IL-17. 
For RA SFMCs were evaluated levels of IL-6, IL-10, IL-4, IFN-γ and IL-17. The 
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general procedure states that standards and samples were diluted with Assay Diluent 
in wells of a 96-wells plate and incubated for 2-3 hours (depending on the ELISA 
kit). Plate was washed 4 times and the specific molecule Conjugated was added into 
the each well. After 1-2 hours of incubation plate was washed again 4 times and 200 
µL Substrate Solution were added to each well. Enzymatic reaction could last up to 
30 minutes and to stop it, 50 µL Stop Solution were added to each well. Plate was 
read at 450 nm with TECAN Sunrise III (Tecan). 
 
Cytokines secretion assay by Flow Cytometry 
PBMCs were activated for 24 hours with Dynabeads Human T-Activator CD3/CD28 
(Life Technologies) and cultured for 3 hours with or without 20 µg/mL CD30/Fc 
chimera (R&D Systems) in RPMI + 10% FCS. Cells were then harvested and tested 
for IL-17 secretion using Cytokine Secretion Assays (Miltenyi Biotec, Bergisch 
Gladbach, D) following manufacturer’s instructions. Briefly, cells were suspended in 
2 mL medium, washed with 2 mL Cold Buffer at 300 x g for 10 minutes and 
resuspended in 90 µL Cold Medium. Cells were incubated 5 minutes on ice with 10 
µL specific cytokine Catch Reagent. Cells were diluted with Warm Medium and 
incubated for 45 minutes at 37° C, washed with Cold Buffer and then labelled with 
PerCp anti-CD3 (Becton Dickinson), PE anti-CD30L (R&D Systems) and APC anti-
IL-17 Detection Antibody. Cells were acquired on a FACSCanto cytometer (Becton 
Dickinson). Analysis was performed with FlowJo 9.3.3 software (Tree Star). 
 
Neutrophils isolation 
Neutrophils from buffy coat of normal subjects were isolated through density 
gradient centrifugation using Lymphoprep Ficoll-Isopaque (Axis-Shield, Oslo, NO) 
according to manufacturer’s instruction. 10 mL PB were diluted with 10 mL PBS and 
then layered over 10 mL Lymphoprep in a 50 mL centrifuge tube. Samples were 
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centrifuged at 800 x g for 20 minutes and cells collected using a Pasteur pipette. 
Obtained cells were putted in a new tube in a final volume of 40 mL PBS. In order to 
achieve erythrocytes sedimentation, 8 mL dextrane were added and after 10-15 
minutes, after phases separation, supernatant was transferred in a new tube. Cells 
were washed with PBS at 1200 rpm for 5 minutes and 7.5 mL NaCl 0.2% were 
added. After 50 seconds 17.5 mL NaCl 1.2% were added, tube was mixed gently and 
washed again with PBS. Cells were then counted using acridin orange staining in a 
Burker chamber and purified using the EasySep Negative Selection Human 
Neutrophil Enrichment Kit (StemCell Technologies, Vancouver, CAN) according to 
manufacturer’s instructions. Briefly, cells were placed in a 5 mL polystyrene tube at a 
concentration of 50 x 106 cells/mL and incubated for 10 minutes with 100 µL 
EasySep Human Neutrophil Enrichment Cocktail. Cells were then incubated with 200 
µL EasySep Nanoparticles for 10 minutes and tube were then placed in a magnet for 
5 minutes. Magnet and tube were inverted and the desired fraction was collected in a 
new tube. Neutrophils were counted as above described. 
 
CD30L expression on neutrophils 
Neutrophils RNA was obtained and retro-transcribed as already described. The 
amplified DNA obtained after RT-PCR was run in a 1.5% agarose gel maintaining a 
constant voltage. In order to analyse CD30L membrane expression, purified 
neutrophils were also pre-incubated with normal human serum (Invitrogen) for 10 
minutes and then incubated with PE anti-CD30L monoclonal antibody (R&D 
Systems) for 20 minutes at RT in the dark. Cells were acquired on a FACSCanto 
cytometer (Becton Dickinson) and analysis was performed with FlowJo 9.3.3 
software (Tree Star). 
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Neutrophils cytokines secretion evaluated by ELISA kit 
Neutrophils were seeded in a 6 wells plate at a final concentration of 2 x 106 cells/mL 
in RPMI + 10% FCS. They were cultured alone, with 20 µg/mL CD30/Fc chimera 
(R&D Systems), with 10 ng/mL LPS (Invitrogen) and finally with both CD30/Fc 
chimera and LPS as a pre-stimulus. Cultures were carried on for 1, 3 and 10 hours; 
Using commercial ELISA kit purchased from R&D Systems (Human Quantikine 
ELISA) were evaluated levels of IL-8, TNF-α, MMP-9, VEGF, IFN-γ and IL-17. In 
general, standards and samples were diluted with Assay Diluent in wells of a 96-
wells plate and incubated for 2-3 hours (depending on the ELISA kit). Plate was 
washed 4 times and the specific molecule Conjugated was added into the each well. 
After 1-2 hours of incubation plate was washed again 4 times and 200 µL Substrate 
Solution were added to each well. Enzymatic reaction could last up to 30 minutes and 
to stop it, 50 µL Stop Solution were added to each well. Plate was read at 450 nm 
with TECAN Sunrise III (Tecan). 
 
Statistical analysis 
Calculations were performed with SPSS statistical package. Quantitative data with a 
normal distribution were expressed as a mean ± SD and were analyzed with Student’s 
t-test. 
A value of p < 0.05 was considered significant. 
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RESULTS 
sCD30 and CD30L in patients’ sera 
We evaluated sCD30 in peripheral blood of healthy donors and RA patients and we 
found a concentration of 13.2 ± 8 ng/mL and of 33.8 19.4 respectively. We also 
evaluated sCD30L levels in peripheral blood of healthy donors and in both peripheral 
blood and synovial fluid of patients affected by RA. We found only a small amount 
of the molecule in controls’ peripheral blood (0.15 ± 0.5 ng/mL) when compared to 
peripheral blood and synovial fluid of RA patients (20 ± 1.54 ng/mL and 23.7 ± 2.83 
ng/mL respectively) (Figure 3A and Table 1). On SDS-PAGE analysis (Figure 3B), 
recombinant sCD30L molecule migrated at approximately 35 kDa under reducing 
conditions. RA patients’ sera show a band with the same molecular weight that was 
immunoprecipitated by CD30/Fc chimera and recognized by anti-human CD30L 
antibody.  
 
sCD30L binds CD30+ T cells 
Jurkat cell line expresses high levels of CD30. To establish whether serum sCD30L is 
able to bind cell surface CD30 molecule, we incubated sera from RA patients with 
known amount of sCD30L (160 and 400 ng/mL) with CD30+ T cells. We used sera of 
normal subjects with undetectable sCD30L as negative control and known amount of 
recombinant sCD30L (6 and 32 µg) as positive controls. The presence of sCD30L on 
cell surface was revealed by the use of an anti-sCD30L antibody. Recombinant 
sCD30L bound CD30+ cells and gave a clear dose-dependent positivity in flow 
cytometry. In the same experiment, the incubation of cells with sera of RA patients 
previously tested in ELISA for the presence of sCD30L gave a clear dose-dependent 
positivity (Figure 3C).  
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sCD30L is a marker of response to anti-TNF-α therapy 
We wanted to evaluate whether sCD30L may correlate with response to anti-TNF-α 
treatment as already reported for sCD30. Indeed we confirmed that RA patients 
responding to TNF-α blockade therapy displayed high levels of sCD30; on the 
contrary an increase of sCD30L concentration was observed in subjects non-
responder to the treatment (Figure 4). Therefore the two molecules behave in a 
different way as possible markers of response to therapy. 
 
sCD30L inhibits Jurkat cells line proliferation by 
inducing cell apoptosis  
We examined whether serum sCD30L was functionally active by evaluating its 
effects on Jurkat cells, a CD30 positive cell line. The incubation of cells with sera 
from RA patients containing high (180 ng/mL) or undetectable sCD30L levels 
induced a 39% or a 9% reduction of proliferation, as compared to normal sera. In 
addition, a neutralizing anti-human CD30L antibody reduced this anti-proliferative 
effect and the inhibition was 18% and 0.5% respectively (Figure 5A). When we 
analyzed the apoptotic index of cells incubated with serum containing high levels of 
sCD30L, we found that it was nearly two and half times higher than apoptosis of cells 
incubated with normal serum suggesting that the inhibition of cells proliferation is 
related, at least in part, with apoptosis of Jurkat cells (Figure 5B).  
 
CD30L shedding 
DG75 cells co-cultured with Karpas-299 cells show a decrease in surface CD30L 
expression by cytofluorimetric analysis. No difference in surface CD30L staining was 
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seen between DG75 cultured alone or in transwell (Figure 6A). Staining was carried 
out before cells seeding, therefore the decrease in CD30L expression is due to the 
shedding of the molecule from cell membrane. These findings suggest that only 
membrane bound CD30 induces CD30L shedding. Indeed in case of internalization 
of the ligand the antibody fluorescence would be detected by the cytofluorimetric 
analysis and there would be no signal difference between DG75 alone and DG75 
cultured with Karpas-299.  
In order to confirm these results, sCD30L was evaluated in the supernatants (Figure 
6B). At 48 and 72 hours, higher levels of sCD30L were found in the supernatant of 
co-cultured cells when compared to the levels found in the supernatant of DG75 
alone (48 hours: co-culture: 4.44 ± 0.22 ng/mL; transwell: 2.47 ± 0.12 ng/mL; DG75 
alone: 2.10 ± 0.10 ng/mL; at 72 hours: 3.46 ± 0.17 ng/mL, 2.72 ± 0.14 ng/mL; 2.22 ± 
0.11 ng/mL in the same conditions. p<0.021 and <0.047 respectively)). 
 
CD30 and CD30L time expression upon cell activation 
In order to find the better conditions in which study the CD30/CD30L signalling we 
investigated the expression of CD30 and CD30L on membrane of activated T cells 
obtained from healthy donors. We observed an increase in CD30L+ cell population 
after 15 hours with a peak at 24 hours of beads stimulation in which slightly more 
then a half of T cells expressed CD30L on their surface (Figure. 7). CD30 expression 
kinetic has a delay compared to that of CD30L and we found 87.6% CD30+ T cells 
after a 48 hours stimulation (Figure 8). 
 
RA patients’ T cells immunophenotype 
The knowledge of the T cell subset predominantly expressing CD30 and CD30L 
present in RA patients’ peripheral blood and synovial fluid (representing the site of 
inflammation) is important in order to understand the role of these cells in RA 
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synovitis, therefore PBMCs and SFMC were collected from 14 RA patients and 8 
controls. CD30+ cells subset is present in the same percentage in peripheral blood of 
both controls and RA patients. In synovial fluid we found a profound difference in 
the CD30+ T cell subset: 8.6% of CD4+ SFMCs are also CD30+ versus 0.5% found in 
control synovial fluid. Treg population is 13.8% of total CD4+ cells in patients while 
is only 4% in controls; in RA 42.3% of Tregs are CD30+ compared to 19% in 
controls (Table 2). 
We did not observe differences in CD30L+ T cell subset percentage between RA 
patients and controls but CD4+CD30L+ subset is larger in synovial fluid of both 
healthy donors and patients. 
 
Cytokines expression induced by CD30 chimera 
In healthy donors activated T cells obtained from peripheral blood showed an 
overexpression of transcripts encoding for IL-17 and a decrease in transcripts coding 
for IFN- γ (except for Normal Control 1 at 48 hours) after incubation with CD30/Fc 
chimera (Figure 9). Activated T cells obtained from the synovial fluid of RA patients 
exposed to CD30/Fc chimera show an upregulation of IL-6 at 15 hours and a down-
regulation at 48 hours while IL-17 displays a general overexpression during the 48 
hours of observation (Figure 10). At 24 hours IFN- γ is downregulated both in 
healthy donors and in the SF of RA patients. 
In order to validate this data from a protein point of view we checked culture 
supernatants looking for cytokines previously investigated. We found detectable 
levels only for IL-17 that results at higher concentrations in samples treated with 
CD30/Fc Chimera (Figures 11,12).  
Moreover in order to understand whether T cells responsible of IL-17 production 
were CD30L+, we performed FACS analysis of cytokine secreting cells. We found 
that in the presence of CD30/Fc chimera, the subset of IL-17 producing cells doubled 
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its number but the percentage of CD30L+ cells decreased (Figure 13) suggesting that 
Th17 are not CD30L+.  
 
Neutrophils express CD30L on their surface 
In order to evaluate that neutrophils express CD30L we studied the presence of this 
molecule at both transcript and protein levels. Retro-transcriptase PCR showed a 
band at 463 bp for both DG75 (our positive control) and neutrophils (Figure 14A). 
FACS analysis revealed the expression of CD30L on neutrophils membrane (Figure 
14B). 
 
Cytokines secretion induced by CD30 chimera on 
neutrophils 
Neutrophils incubated with CD30/Fc chimera and with LPS as stimulatory molecule, 
displayed a level of IL-8 secreted into culture media much higher that when 
incubated with CD30/Fc chimera or with LPS alone. Similarly MMP-9 showed an 
important decrease when neutrophils were incubated with CD30/Fc chimera and with 
LPS indicating that CD30/Fc chimera may have an inhibitory effect on the release of 
this metalloprotease (Figure 15). The other analyzed molecules did not displayed any 
significant difference with or without CD30/Fc chimera or were undetectable. 
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DISCUSSION AND CONCLUSIONS 
The knowledge of the signalling upon CD30/CD30L engagement has been hampered 
by the difficulty to clarify the inhibitory or activating signals induced by the binding 
of cells expressing either or both molecules. Moreover the presence of sCD30 makes 
the picture even more confused, since it can either inhibit the activation of CD30+ T 
cells by blocking the CD30 molecule engagement by CD30L+ T cells or activate or 
block CD30L+ T cells by inducing a reverse signalling that can inhibit the production 
of type 1 cytokines. Since the levels of soluble CD30 seem to reflect the preferential 
proliferation of Th2 phenotype and the production of antinflammatory cytokines, it is 
not surprising that the presence of high levels of sCD30 in patients with RA is 
indicative of a good response to therapy both with classical DMARDs and with 
biological agents.  
 
Very little is known on the presence, biological activity and correlation with response 
to therapy, of sCD30L. We observed that CD30L+ T cells preferentially release the 
soluble molecule upon direct cell-cell contact as happens for the release of sCD30. 
Moreover the presence of high levels of sCD30L in the sera and SF of patients with 
RA fits with the hypothesis that sCD30L reflects a preferential expansion of CD30L+ 
T cells and that this cell subtype is mainly of the Th1 phenotype. It is therefore not 
surprising that high levels of sCD30L are present in patients who are unresponsive to 
biological treatment. 
The conclusion of this first part of experiments is that sCD30 and sCD30L behaves 
differently in the course of the treatment of RA and may be used as markers to 
predict the response to therapy.  
 
The ability of sCD30L to bind CD30+ cells indicates that it has the correct folding 
and can maintain the capacity to be functionally active. Indeed our data show that 
sCD30L is able to inhibit CD30+ T cell proliferation. The partial restore of cell 
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proliferation in the presence of a specific neutralizing anti-CD30L antibody confirms 
the involvement of sCD30L in inhibition of cell proliferation. Such inhibition is at 
least in part due to a mechanism of cell apoptosis and may play a pivotal role in the 
maintenance of inflammation, since CD30+ T cells are known to be mainly of the Th2 
phenotype, producing antinflammatory cytokines. 
Altogether these data show that sCD30L is functionally active since it is able to bind 
CD30+ T cells and inhibit their proliferation through the ability to induce CD30+ cell 
apoptosis. 
 
The hypothesis that CD30L+ and CD30+ T cells belong to Th1 and Th2 phenotype, 
respectively, is further supported by our observations about the time of expression of 
these two molecules upon activation of T cells with anti-CD3 and anti-CD28 beads: 
CD30L is mainly exposed on the cell surface within 24 hours from activation, 
suggesting that CD30L+ T cells may be involved in the beginning of inflammation 
(Th1 phenotype) while CD30 molecule is mainly exposed after 48 hours from 
activation, suggesting a possible role of CD30+ T cells in downmodulating 
inflammation (Th2 phenotype).  
 
We then studied the cytokine production upon stimulation of PBMCs or SFMC with 
CD30 chimera, by real time PCR. The cytokine levels and the cell cytokines secretion 
analysis are consistent with an increase of IL-17 (at both transcript and protein levels) 
suggesting that CD30/CD30L signalling is involved in polarizing the Th17 response, 
as already observed in the murine model. Decrease in CD30L+ cells percentage 
observed in IL-17 producing cell assay could be explained by two side effects of 
CD30/Fc chimera: shedding of CD30L or the impossibility of anti-CD30L antibody 
to bind membrane CD30L engaged by the CD30/Fc chimera. 
Some limitations in studying cytokines productions by PBMCs or SFMCs stimulated 
with CD30/Fc chimera must be taken into account. First of all results of real time 
PCR must be handled with caution because PBMCs are composed by heterogeneous 
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cell subsets and collected RNA belongs to different kind of cells. Secondly the 
simultaneous presence of CD30+ and CD30L+ cells and of sCD30 and sCD30L may 
interfere with the stimulation provided by CD30/Fc chimera. 
Therefore the data obtained in this part of the project need to be further confirmed. If 
the data will be confirmed, we can conclude that surface CD30L is able to favor the 
polarization of T cells towards a Th17 phenotype with proinflammatory features. 
 
Neutrophils express CD30L and once activated by LPS and stimulated by CD30/Fc 
chimera show the ability to produce a proinflammatory cytokine (IL-8), able to 
further recruit neutrophils at site of inflammation. Less clear is the inhibition in 
MMP-9 secretion since MMP-9 is involved in bone erosion. This result needs to be 
confirmed.  
 
Finally it is interesting to analyze the percentage of T cells expressing CD30 in the 
synovial fluid of patients with RA. Indeed the percentage of CD4+CD30+ T cells is 
much higher in the synovial fluid of patients compared with controls and the number 
of Treg cells expressing CD30 is again higher in patients than controls. Altogether 
these data indicate that there is an attempt to downmodulate inflammation in order to 
control the disease progression at site of chronic inflammation, ie: rheumatoid 
synovitis. 
 
In conclusion the study of sCD30 and sCD30L molecules as well as CD30+ and 
CD30+ T cells helps in clarifying the complex pro- and antinflammatory mechanisms 
that are present in Rheumatoid Arthritis and possibly pave new avenues for the 
understanding of the response to therapy and envisage the possibility of novel 
treatments directed against the CD30L molecule.   
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TABLES  
Table1. Characteristics of patients and controls and levels of soluble CD30 and CD30L.	  
	  
	  
Table 2. CD30+ and CD30L+ T cells phenotype in the peripheral blood (PB) and synovial fluid 
(SF) of RA patients and controls. 
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FIGURES 
	  
	  
     Nat Rev Rheumatol, August 2012 
Figure 1. Proposed mechanism of initiation of RA. 
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Nat Rev Immunol, August 2010 
Figure 2. Years from the break of self tolerance to the onset of clinical manifestations. 
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Figure 3. sCD30L in RA patients’ sera bind CD+T cells.  
A) Level of sCD30L in healthy donors’ peripheral blood (Controls), in RA patients’ peripheral 
blood (Serum) and synovial fluid (SF); B) Immunoprecipitation of sCD30L from sera of RA 
patients and control (lane 1: human recombinant sCD30L; lane 2: serum of RA patient; lane 3: 
serum of RA patient; lane 4: serum of healthy donor) C) Ability of recombinant sCD30L (blue and 
light blue curves: 6 and 32 µg) and of sCD30L obtained from RA patients’ sera, at two different 
concentrations (orange and red curves: 160 and 400 ng/mL respectively) to bind membrane CD30 
on Jurkat cell line. 
	  
	  
Figure 4. sCD30 and sCD30L are marker of response to anti-TNF-α therapy.  
On the Left: high levels of sCD30L are indicative of lack of response to anti-TNF-α treatment. On 
the right: high levels of sCD30 are a marker of good response to therapy. 
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Figure 5. sCD30L inhibits Jurkat proliferation.  
A)(1) CD30+ T cell line (Jurkat) was cultured with a RA patient’s serum containing high levels of 
sCD30L (white bar) and with the same serum using an anti-CD30L blocking antibody (grey bar). 
(2) CD30+ cells cultured with a RA patient’s serum with undetectable levels of sCD30L (white bar) 
and CD30+ cells cultured with the same serum and an anti-CD30L blocking antibody (grey bar); B) 
Apoptotic index of Jurkat cells incubated with RA patient’s serum containing high (1) or 
undetectable (2) levels of sCD30L. 
 
	  
Figure 6. CD30L shedding.  
A) FACS analysis of sCD30L expression of DG75 alone (grey curve), cultured in transwell (blue 
curve) and co-cultured with Karpas-299 (red curve); B) sCD30L levels in supernatant of DG75 
alone (grey bar), cultured in transwell (blue bar) and co-cultured with Karpas-299 (red bar).  
* indicates a p Value < 0.05 
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Figure 7. Surface CD30L expression upon cell activation. 
Percentage of CD30L+ T cells rapidly increases in the first 15 hours reaching the maximum value 
(52.4%) after 24 hours  
	  
	  
	   62	  
	  
Figure 8. Surface CD30 expression upon cell activation.  
Percentage of CD30+ T cells increases until reaches its the maximum value (87.6%) after 48 hours. 
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Figure 9. Modulation of cytokines gene expression in activated PBMCs following incubation 
with CD30/Fc chimera in normal subjects.  
Transcripts coding for IL-17 are upregulated while those coding for IFN-γ (except for Normal 
Control 1 at 48 hours) are downregulated.  
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Figure 10. Modulation of cytokines gene expression in activated SFMCs following incubation 
with CD30/Fc chimera in patients with RA. 
Transcripts coding for IL-6 show an upregulation at 15 hours and a downregulation at 48 hours 
while IL-17 displays a general overexpression during the 48 hours of observation. At 24 hours IFN-
γ is downregulated. The three patients display a different behavior probably related also to disease 
duration. 
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Figure 11. Levels of IL-17 released in the medium by activated PBMCs in presence or absence 
of CD30/Fc chimera in healthy donors. 
CD30/Fc chimera stimulus induces the production of IL-17 at 48 hours 
* indicates a p Value < 0.05 
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Figure 12. Levels of IL-17 released in the medium by activated SFMCs in presence or absence 
of CD30/Fc chimera in RA patients. 
CD30/Fc chimera stimulus induces the production of IL-17 at 48 hours 
* indicates a p Value < 0.05 
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Figure 13. FACS analysis of IL-17 producing cells on healthy donor’s activated PBMCs 
stimulated with CD30/Fc chimera.  
After 3 hours of CD30/Fc chimera stimulation the percentage of IL-17 producing T cell is 2.749% 
while in the control is of 1.115% 
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Figure 14. Neutrophils express CD30L.  
A) Gel electrophoresis of RT-PCR products obtained from CD30L transcripts in Neutrophils (lane 
4) and DG75 (lane 5) and their negative controls (lane 2 and 3 respectively); B) CD30L surface 
expression obtained with FACS analysis. 
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Figure 15. Levels of molecules released in the medium by healthy donor’s neutrophils in 
presence or absence of CD30/Fc chimera and activated or not with LPS .  
Upper box: Neutrophils incubated with CD30/Fc chimera and with LPS displayed the highest level 
of IL-8 production. Lower box: MMP-9 is decreased in the supernatant of neutrophils stimulated 
with LPS and CD30/Fc chimera. 
* indicates a p Value < 0.05 
	  
